Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857233 | 0.91 | APLNR (0.42) | APLNRCA2CA12CA14TDP1 | |
| SCHEMBL24506767 | 0.83 | APLNR (0.42) | APLNRCA2CA12CA14TDP1 | |
| SCHEMBL22030517 | 0.83 | CA12 (0.46) | APLNRCA2CA12CA14TDP1 | |
| SCHEMBL12662923 | 0.83 | APLNR (0.37) | APLNRCA2CA12CA14TDP1 | |
| SCHEMBL12155186 | 0.81 | APLNR (0.43) | APLNRCA2CA12CA14TDP1 | |
| SCHEMBL16747755 | 0.78 | APLNR (0.41) | APLNRCA2CA12CA14TDP1 | |
| SCHEMBL14077932 | 0.77 | MAOA (0.45) | APLNRCA2CA12CA14TDP1 | |
| SCHEMBL307685 | 0.77 | APLNR (0.43) | APLNRCA2CA12CA14TDP1 | |
| SCHEMBL12337377 | 0.77 | APLNR (0.33) | APLNRCA2CA12CA14CA1 | |
| SCHEMBL16789211 | 0.76 | APLNR (0.42) | APLNRCA2CA12CA14TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536375-B2 | Synthesis of obtaining modified polyethylene glycol intermediates | GE HEALTHCARE LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| US-8536375-B2 | Synthesis of obtaining modified polyethylene glycol intermediates | GE HEALTHCARE LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| US-8415510-B2 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LIMITED (GB) | 2013-04-09 | — | — | US | disclosed |
| US-8415510-B2 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LIMITED (GB) | 2013-04-09 | — | — | US | disclosed |
| US-20120004423-A1 | SYNTHESIS OF OBTAINING MODIFIED POLYETHYLENE GLYCOL INTERMEDIATES | GE HEALTHCARE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20120004423-A1 | SYNTHESIS OF OBTAINING MODIFIED POLYETHYLENE GLYCOL INTERMEDIATES | GE HEALTHCARE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| WO-2010074935-A1 | SYNTHESIS OF OBTAINING MODIFIED POLYETHYLENE GLYCOL INTERMEDIATES | GE HEALTHCARE LIMITED (GB) | 2010-07-01 | — | — | WO | disclosed |
| WO-2009108484-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004423-A1 | SYNTHESIS OF OBTAINING MODIFIED POLYETHYLENE GLYCOL INTERMEDIATES | COASY, DHPS, FASN | APLNR 226/4885CA2 4614/4885CA12 2226/4885 |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GAS6, LNPEP, BMP6 | APLNR 167/4885CA2 4294/4885CA12 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.